Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
  • InderesTV
  • Portfölj
  • Forum
  • Q&A
  • Om oss
    • Bolag under bevakning
    • Teamet

Du verkar använda en bredare skärm. Vill du aktivera en bredare visningsupplevelse på denna sida?

Ascelia Pharma - Podcast with Deputy CEO Julie Waras Brogren and CSO Andreas Norlin

Av Claus ThestrupCEO, Sweden
Ascelia Pharma

We have sat down with Ascelia Pharma Deputy CEO Julie Waras Brogren and CSO Andreas Norlin. In this podcast, we are covering the following topics:

Warrant TO1 - Exercise period ongoing:  Subscription period, price, and price calculation. What are gross proceeds at 100% participation?

Feedback from presenting Orviglance abstracts at scientific conferences: RSNA, Society of Abdominal Radiology Congress, ESGAR, ISPOR. What kind of feedback do you receive from the scientific community ie. clinicians, physicians, and KOL?  Do payers, policymakers, healthcare providers, patient organizations, and industry players participate?

Discussions with the FDA: Ascelia Pharma received a positive outcome from the FDA and are ready to file their NDA in mid-2025. What is the format when you discuss with the FDA?

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharam for a Corporate Visibility/Digital IR subscription agreement. /Claus Thestrup, 11.24 AM, 11 April 2025.

Recent videos

Life Science Companies as Investments | Life Science Night Dec. 9, 2025
2025-12-16 08:30 Aiforia Technologies
Truecaller, Webcast, Press Conference, 2025
2025-12-15 13:00 Truecaller
Herantis Pharma as an Investment | Life Science Night Dec 9, 2025
2025-12-15 13:00 Herantis Pharma
Orion as an Investment | Life Science Night Dec. 9, 2025
2025-12-13 12:50 Orion
A sit-down with CEO Remco Westermann
2025-12-12 09:09 Verve Group
Titta på alla videos
Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.